TAK
Takeda Pharmaceutical Co Ltd
17.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -86.0% | +925.3% | +44.6% | -13.1% | +103.9% | +50.9% | +11.1% | -13.0% | -26.7% | +47.6% | -1.5% | |
| – | -24.4% | -13.1% | +6.2% | +36.0% | +135.6% | -4.1% | +4.2% | +13.9% | +9.6% | +4.6% | -5.3% | |
| – | -27.7% | +4.6% | +21.0% | +7.9% | +45.0% | +29.3% | +15.2% | +39.9% | +16.8% | +2.8% | -0.1% | |
| – | – | -320.7% | – | – | – | – | – | -87.6% | – | – | – | |
| – | -201.9% | – | -54.8% | +377.3% | +48.0% | +191.3% | -64.2% | -125.6% | – | – | – | |
| – | -21.9% | +32.0% | +14.5% | +4.6% | +62.3% | +8.6% | -21.3% | +240.6% | -24.1% | -21.0% | +9.2% | |
| – | -178.0% | +820.8% | -85.8% | +2,938.0% | – | +34.7% | -150.3% | +206.4% | -23.6% | -20.9% | +0.6% | |
| – | -0.1% | +0.1% | +0.1% | +0.7% | +97.7% | +0.3% | +0.1% | -1.5% | +2.8% | +5.3% | +3.1% | |
| – | +27.1% | +3.5% | -18.9% | -93.8% | +218.9% | -42.7% | +3,521.3% | -65.3% | -91.4% | +2,129.6% | -0.5% | |
| – | – | +926.7% | -132.5% | – | -118.5% | +12.7% | -9.1% | -52.5% | – | -20,874.2% | – | |
| – | -58.5% | – | -212.5% | – | -134.1% | +8.3% | -1.7% | -33.7% | -50.0% | +112.0% | -33.9% | |
| – | – | – | – | – | -116.0% | – | -135.5% | – | – | – | – | |
| – | -180.4% | – | +67.1% | -22.1% | +132.6% | +71.3% | +21.0% | -63.3% | -31.4% | +187.6% | -7.5% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.